Mining the Plasma Proteome for Insights into the Molecular Pathology of Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 2022; 205:1449-1460.
.COL18A1 genotypic associations with endostatin levels and clinical features in pulmonary arterial hypertension: a quantitative trait association study. ERJ Open Research. 2022; 8.
.Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. European Respiratory Journal. 2022; 59.
.Parkinson Disease and Subthalamic Nucleus Deep Brain Stimulation: Cognitive Effects in GBA Mutation Carriers. Annals of Neurology. 2022; 91:424-435.
.Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension. Journal of Pediatrics. 2022; 241:68-76.e3.
.Hepatoma-derived growth factor is associated with pulmonary vascular remodeling and PAH disease severity and survival. Pulmonary Circulation. 2022; 12.
.Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH. Genome Medicine. 2021; 13.
.Angiostatic Peptide, Endostatin, Predicts Severity in Pediatric Congenital Heart Disease-Associated Pulmonary Hypertension. Journal of the American Heart Association. 2021; 10.
.The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension. ERJ Open Research. 2021; 7.
.Subthalamic Peak Beta Ratio Is Asymmetric in Glucocerebrosidase Mutation Carriers With Parkinson's Disease: A Pilot Study. Frontiers in Neurology. 2021; 12.
.(2021) ST2 Is a Biomarker of Pediatric Pulmonary Arterial Hypertension Severity and Clinical Worsening. 160:297-306.
.NHLBI-CMREF Workshop Report on Pulmonary Vascular Disease Classification: JACC State-of-the-Art Review. Journal of the American College of Cardiology. 2021; 77:2040-2052.
.Cognitive Functioning of Glucocerebrosidase (GBA) Non-manifesting Carriers. Frontiers in Neurology. 2021; 12.
.Bayesian Inference Associates Rare KDR Variants with Specific Phenotypes in Pulmonary Arterial Hypertension. Circulation: Genomic and Precision Medicine. 2021; 14.
.United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics. Chest. 2021; 159:311-327.
.Pediatric pulmonary hypertension: insulin-like growth factor-binding protein 2 is a novel marker associated with disease severity and survival. Pediatric Research. 2020; 88:850-856.
.Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. BMC Medicine. 2020; 18.
.Whole-Blood RNA Profiles Associated with Pulmonary Arterial Hypertension and Clinical Outcome. American Journal of Respiratory and Critical Care Medicine. 2020; 202:586-594.
.Elevated Interleukin-6 Levels Predict Clinical Worsening in Pediatric Pulmonary Arterial Hypertension. Journal of Pediatrics. 2020; 223:164-169.e1.
.A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype. Pulmonary Circulation. 2020; 10.
.Novel Mutations and Decreased Expression of the Epigenetic Regulator TET2 in Pulmonary Arterial Hypertension. Circulation. 2020; 141:1986-2000.
.Genetic Admixture and Survival in Diverse Populations with Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine. 2020; 201:1407-1415.
.Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension. Chest. 2020; 157:1606-1616.
.Cellular sources of interleukin-6 and associations with clinical phenotypes and outcomes in pulmonary arterial hypertension. European Respiratory Journal. 2020; 55.
.Mendelian randomisation analysis of red cell distribution width in pulmonary arterial hypertension. European Respiratory Journal. 2020; 55.
.The EYA3 tyrosine phosphatase activity promotes pulmonary vascular remodeling in pulmonary arterial hypertension. Nature Communications. 2019; 10.
.Novel risk genes and mechanisms implicated by exome sequencing of 2572 individuals with pulmonary arterial hypertension. Genome Medicine. 2019; 11.
.Phenotype characterisation of TBX4 mutation and deletion carriers with neonatal and paediatric pulmonary hypertension. European Respiratory Journal. 2019; 54.
.United States Pulmonary Hypertension Scientific Registry (USPHSR): rationale, design, and clinical implications. Pulmonary Circulation. 2019; 9.
.Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis. The Lancet Respiratory Medicine. 2019; 7:227-238.
.Genetics and genomics of pulmonary arterial hypertension. European Respiratory Journal. 2019; 53.
.Hypoxia-induced Pulmonary Hypertension in Different Mouse Strains: Relation to Transcriptome. American Journal of Respiratory Cell and Molecular Biology. 2019; 60:106-116.
.Rare variants in SOX17 are associated with pulmonary arterial hypertension with congenital heart disease. Genome Medicine. 2018; 10.
.Alpha galactosidase A activity in Parkinson's disease. Neurobiology of Disease. 2018; 112:85-90.
.Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults. Circulation: Genomic and Precision Medicine. 2018; 11.
.2018; 37.
. (497) The United States Pulmonary Hypertension Scientific Registry (USPHSR): Objectives and Preliminary Data. Journal of Heart Transplantation.